Treatment of acute myeloid leukemia

Haematologica

Volumn 94, Issue 1, 2009, Pages 10-16

  Estey, Elihu H ^a  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BILIRUBIN; CLOFARABINE; CREATININE; CYTARABINE; FLT3 LIGAND; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; TIPIFARNIB; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CHROMOSOME 16; COMORBIDITY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; FALSE NEGATIVE RESULT; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA REMISSION; LOW DRUG DOSE; PERICENTRIC CHROMOSOME INVERSION; PROGNOSIS; REVIEW; THERAPY EFFECT; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CYTOGENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 58149214243     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.2008.001263     Document Type: Review

References (33)

1. Morra E, Barosi G, Bosi A, Ferrara F, Locatelli F, Marchetti M, et al. Clinical management of primary non-APL acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2009;94:102-12.
2. Schlenk RF, Dohner K, Kneba M, Gotze K, Hartmann F, Valle Fd, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia-results from the AMLSG trial AML HD98B. Haematologica 2009;94:54-60.
3. Estey EH, Bedikian SH, Witter DC, Pierce SA, Giles FJ. The predictive value of a "Positive" ASH abstract in AML therapeutics. Blood 2006;108:abstract#1964.
4. Thall P, Estey E. Graphical methods for evaluating covariate effects in the Cox model. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology New York:Marcel-Dekker 2001:411-33.
5. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-907.
6. Estey E, Smith TL, Keating MJ, McCredie KB, Gehan EA, Freireich EJ. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989;3:257-63.
7. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007;136:624-7.
8. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
9. Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol 2008;35:410-7.
10. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-9.
11. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.
12. Burnett AK, Kell WJ, Goldstone AH, Milligan D, Hunter A, Prentice AG, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary anlysis of 1115 patients in the MRC AML15 trial. Blood 2006;108:abstract #13.
13. Borthakur G, Kantarjian H, Wang X, Plunkett WK Jr, Gandhi VV, Faderl S, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 2008;113:3181-5.
14. Mrozek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008;35:365-77.
15. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26:4791-7.
16. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-83.
17. de Lima M, Strom SS, Keating M, Kantarjian H, Pierce S, O'Brien S, et al. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood 1997;90:4719-24.
18. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-48.
19. Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2008 Sep 30. [Epub ahead of print].
20. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007;109:3658-66.
21. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2007;109:1395-400.
22. Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008;35:388-400.
23. Freireich EJ, Gehan EA, Sulman D, Boggs DR, Frei E 3rd. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 1961;14:593-608.
24. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244-54.
25. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9.
26. Estey E, Sun Z, Rowe J, Faderl S, Cassileth P, Sartiano G, et al. A 3,239-patient combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) analysis of the effect of CR vs. responses
27. Estey EH, Garcia-Manero G, Giles FJ, Cortes J, O'Brien S, Kantarjian HM. Clinical relevance of CRp in untreated AML. Blood 2005;106:abstract#541.
28. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-903.
29. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7.
30. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24.
31. Estey E. New drugs in acute myeloid leukemia. Semin Oncol 2008;35:439-48.
32. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 2003;102:442-8.
33. Wathen JK, Thall PF, Cook JD, Estey EH. Accounting for patient heterogeneity in phase II clinical trials. Stat Med 2008;27:2802-15.